1. The role of thioredoxin system in cancer: strategy for cancer therapy

   • Jin-Jing Jia
   • Wen-Shuo Geng
   • Xian-Si Zeng

   Review Article 11 May 2019 Pages: 453 - 470

   

2. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

   • Marie Lindhard Madsen
   • Hanne Due
   • Karen Dybkær

   Review Article Open access 18 June 2019 Pages: 471 - 485

3. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

   • Maarten van Eijk
   • René J. Boosman
   • Jos H. Beijnen

   Review Article Open access 15 July 2019 Pages: 487 - 499

   

4. Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

   • Yvonne Y. Lau
   • Wen Gu
   • Patrick Urban

   Original Article 24 April 2019 Pages: 501 - 511

   

5. Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment

   • Oznur Yigit
   • Mavis Emel Kulak Kayikci
   • Erol Belgin

   Original Article 17 April 2019 Pages: 513 - 520

   

6. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha

   • Faruk Tas
   • Kayhan Erturk

   Original Article 17 April 2019 Pages: 521 - 526

   

7. In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models

   • Qi Weng
   • Leilei Zhou
   • Qingyong Li

   Original Article 27 April 2019 Pages: 527 - 537

   

8. Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

   • Whitney P. Kirschbrown
   • Bei Wang
   • Amit Garg

   Original Article Open access 10 June 2019 Pages: 539 - 550

   

9. Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells

   • Aehtesham Hussain
   • Mohd Saleem Dar
   • Mohd Jamal Dar

   Original Article 25 May 2019 Pages: 551 - 559

   

10. Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

    • Masaki Shiota
    • Motonobu Nakamura
    • Masatoshi Eto

    Original Article 21 May 2019 Pages: 561 - 566

    

11. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer

    • Sanjay Goel
    • Umang Swami
    • Daniel P. Petrylak

    Original Article 12 June 2019 Pages: 567 - 578

    

12. Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors

    • Rex M. Philpot
    • M. Ficken
    • L. Wecker

    Original Article 13 July 2019 Pages: 579 - 589

    

13. Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study

    • Sofya Pintova
    • Sirish Dharmupari
    • Randall F. Holcombe

    Original Article 15 June 2019 Pages: 591 - 598

    

14. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients

    • Xuan Jin
    • Yu Bai
    • Shikai Wu

    Original Article 15 June 2019 Pages: 599 - 607

15. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

    • Lu Cao
    • Guomin Xiang
    • Yun Niu

    Original Article 11 July 2019 Pages: 609 - 620

    

16. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

    • Elodie Valade
    • Anne-Gaëlle Dosne
    • Daniele Ouellet

    Original Article 06 July 2019 Pages: 621 - 633

    

17. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response

    • Xing Xu
    • Guoliang Zheng
    • Zhichao Zheng

    Original Article 22 June 2019 Pages: 635 - 646

    

18. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients

    • Utako Ishimoto
    • Akiyoshi Kinoshita
    • Masayuki Saruta

    Original Article 22 June 2019 Pages: 647 - 654

    

19. Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study

    • Mie Kotake
    • Hisao Imai
    • Koichi Minato

    Original Article Open access 27 June 2019 Pages: 655 - 660

    

20. Rituximab dosing in hematological malignancies: an old question, revisited

    • Peter N. Morcos
    • Axel Boehnke
    • Donald E. Mager

    Short Communication 21 March 2019 Pages: 661 - 666

    

21. Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin^®) in patients with HER2‑positive metastatic breast cancer

    • Xiaoying Chen
    • Cheryl Li
    • Donghua Yin

    Correction Open access 10 July 2019 Pages: 667 - 667